Loading
NASDAQHealthcareBiotechnology
Latest quote
$43.07
+$1.12 · +2.67%
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Previous close
$43.07
+$1.12 · +2.67%
Regular session · ET · Market data may be delayed.
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Day range
Current $43.07
52-week range
Current $43.07
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
39
Expensive
Sentiment
67
Bullish
Risk
35
Moderate Risk
Momentum
72
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Day range
Current $43.07
52-week range
Current $43.07
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 2.27M USD | — | — | — | — |
| Gross profit | −2.27M USD | — | — | — | — |
| Research and development | 151.39M USD | 126.97M USD | 90.91M USD | 54.03M USD | 32.19M USD |
| Selling, general, and administrative | 40.02M USD | 31.87M USD | 23.45M USD | 17.63M USD | 11.03M USD |
| Operating expenses | 189.14M USD | 158.83M USD | 114.36M USD | 71.66M USD | 43.22M USD |
| Interest income | 23.61M USD | 25.02M USD | 14.19M USD | 2.66M USD | 402K USD |
| Interest expense | — | — | — | 4.02M USD | — |
| Depreciation and amortization | 2.27M USD | 2.29M USD | 1.73M USD | 538K USD | 272K USD |
| Operating income | −191.41M USD | −158.83M USD | −114.36M USD | −71.66M USD | −43.22M USD |
| Net income | −167.8M USD | −133.81M USD | −100.16M USD | −67.64M USD | −42.81M USD |
Company facts updated Sep 5, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$51.90
20.50% upsidePrice history unavailable
High $66.00Average $51.90Low $36.00Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI111.94M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM76.82M0.10%79.88B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF33.38M0.03%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Growth ETFIWO27.88M0.19%14.58B USD0.24%$377.54+0.12%
iShares Biotechnology ETFIBB24.65M0.23%10.72B USD0.44%$211.92-0.88%
Vanguard Russell 2000 ETFVTWO15.42M0.09%17.4B USD0.06%$119.62+0.25%
Schwab U.S. Small-Cap ETFSCHA15.2M0.07%22.56B USD0.03%$34.55+1.01%
State Street SPDR S&P Pharmaceuticals ETFXPH11.9M1.92%620.88M USD0.35%$70.93-0.14%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAState Street SPDR S&P Pharmaceuticals ETFXPHAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
